GlaxoSmithKline encountered some stiff industry headwinds when it pledged to open up its data vault to outside investigators. But as of today it has a high-profile convert on its side. The biopharma giant Roche has agreed to follow in GSK's footsteps, saying that it will work with an independent group which will be charged with sorting out and approving requests for access to anonymized clinical trial data for all approved products. If regulators can't provide the data, says Roche, then the company will make it available.
Over the past few days I've met with dozens of people in the U.K.'s biotech industry, getting a crash course on the state of affairs here while getting a chance to offer a few opinions of my own on global drug development trends at a One Nucleus gathering at Canada House. More >>
Don't be fooled by the overflow of news on stock swings and megabucks involved in biotech; many people--and I would guess most--become enamored with this industry because of the promise of transforming scientific discoveries into new therapies. Bank on 2013 being a year when real innovators in life sciences with bold ideas look like smart businesspeople too. Read more >>
Now more than a year into an R&D experiment to foster closer ties with academia, Pfizer ($PFE) has won over some top researchers with an open-arms approach to advancing science from labs to the clinic.
One of the most intriguing new developments in the drug discovery field has been the recruitment of gamers into the puzzling business of protein folding. Now an initial foray into simple puzzle
Novo Nordisk ( $NVO ) is setting up a new R&D center in Seattle that aims at reengineering the model for early-stage drug work and speeding up development in the diabetes field. Under the direction
Throughout 2011 we've seen a continuation of an intense reengineering of the development process at a slate of Big Pharma companies. Pfizer ( $PFE ), of course, grabbed the biggest headlines as it
Sanford-Burnham Medical Research Institute in La Jolla, CA has joined the growing list of scientific groups to team up with Pfizer on its new effort to spur translational medicine programs for
Open source, collaborative discovery models are all the rage these days. Researchers interested in vetting their compound's potential while looking for the opportunity to hook up with a pharma giant
With R&D expenses expected to surge 13 percent this year at Bayer, Germany's largest drug company, CEO Marijn Dekkers is telling reporters that he plans to make sure the budget item flatlines at